Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database

Association Between Gastrointestinal Events and Persistence with Osteoporosis Therapy: Analysis of Administrative Claims of a U.S. Managed Care Population

“…15,[18][19][20][21][22][23] Multiple studies indicate that medication side effects may be one of the key factors influencing patients' suboptimal treatment persistence and adherence behavior. [24][25][26] Gastrointestinal (GI) events are common among patients receiving bisphosphonate therapy for the treatment of osteoporosis.…”

“…In previous database studies in the United States and Europe, 17%-58% of patients were persistent with bisphosphonate therapy during the first year of treatment, and our mean persistence rate (39.3%) is within this range. [17][18][19]21,30 The wide range in previously reported studies is likely a function of differences in study methodology, oral bisphosphonate dosing schedule (e.g., daily vs. weekly), and patient characteristics (e.g., men vs. women). For example, we used a medication supply gap of 45 days or less to define persistence, and the supply gap in earlier studies ranged from 30-183 days, with larger gaps typically resulting in greater persistence rates.…”

“…20 Ulcer of esophagus without bleeding 530. 21 Ulcer of esophagus with bleeding X 530. 3 Stricture of esophagus 530.…”

Identifikation, Diagnostik und leitliniengerechte Osteoporosetherapie (DVO) unfallchirurgischer Patienten

“…möglich. Die Einnahmefrequenz ist auch unter dem Aspekt der Compliance zu erwägen: die Compliance ist eher besser, je geringer die Einnahmefrequenz ist [47].…”

Compliance with osteoporosis medications – an underestimated determinant of anti-fracture efficacy

“…It appears quite low with oral medications. In general, 40-50% of patients on oral bisphosphonates (mainly alendronate and risedronate) 2 or raloxifene 3 remain on treatment at 12 or 24 months. The magnitude of the effect of non-compliance on the increase in fracture risk can be further realized if one takes into account that it is comparable to the effect of osteoporosis medication on fracture risk reduction 4 .…”